<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2650">
  <stage>Registered</stage>
  <submitdate>26/01/2010</submitdate>
  <approvaldate>26/01/2010</approvaldate>
  <nctid>NCT01058083</nctid>
  <trial_identification>
    <studytitle>Safety Study of BMS-770767 in Subjects With Hypercholesterolemia</studytitle>
    <scientifictitle>A Double-blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Primary Hypercholesterolemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-014306-33</secondaryid>
    <secondaryid>MB117-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dyslipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-770767
Treatment: drugs - BMS-770767
Treatment: drugs - BMS-770767
Treatment: drugs - BMS-770767
Treatment: drugs - Placebo

Experimental: BMS-770767 (Treatment A) - 

Experimental: BMS-770767 (Treatment B) - 

Experimental: BMS-770767 (Treatment C) - 

Experimental: BMS-770767 (Treatment D) - 

Placebo Comparator: Placebo (Treatment E) - 


Treatment: drugs: BMS-770767
Active, Oral, 15 mg, Daily, 28 days

Treatment: drugs: BMS-770767
Active, Oral, 50 mg, Daily, 28 days

Treatment: drugs: BMS-770767
Active, Oral, 150 mg, Daily, 28 days

Treatment: drugs: BMS-770767
Active, Oral, 50 mg BID, Daily, 28 days

Treatment: drugs: Placebo
Placebo, Oral, 0 mg, daily, 28 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lowering of LDL-C</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (Blood Level) of BMS-770767</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamic effects of BMS-770767 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, non-esterified free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Hypercholesterolemia

          -  Currently taking a stable daily dose of statin therapy

          -  Serum triglyceride level &lt; 500mg/dl</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  History of myocardial infarction, coronary angioplasty or bypass grafts, valvular
             disease or repair, unstable angina pectoris, transient ischemic attack, or
             cerebrovascular accidents within six months prior to entry into the study

          -  Congestive heart failure

          -  Diabetes mellitus

          -  Active liver disease

          -  Impaired renal function

          -  Hepatitis C, B and HIV

        This list is not inclusive additional information is provided in the protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA</recruitmentstate>
    <hospital>Local Institution - Blacktown</hospital>
    <hospital>Local Institution - Hornsby</hospital>
    <hospital>Local Institution - Caboolture</hospital>
    <hospital>Local Institution - South Brisbane</hospital>
    <hospital>Local Institution - Daw Park</hospital>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode>2077 - Hornsby</postcode>
    <postcode>4510 - Caboolture</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5041 - Daw Park</postcode>
    <postcode>6004 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Prince Edward Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects
      on LDL cholesterol (LDL-C)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01058083</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>